Haleon (LON:HLN) Price Target Raised to GBX 514

Haleon (LON:HLN) had its price target hoisted by Berenberg Bank from GBX 512 to GBX 514 in a research note published on Wednesday, Marketbeat reports. They currently have a buy rating on the stock.

Several other research analysts also recently commented on HLN. JPMorgan Chase & Co. reduced their price target on shares of Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a research note on Thursday, June 25th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Haleon from GBX 325 to GBX 335 and gave the stock a “sell” rating in a research note on Friday, July 31st. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 400 target price on shares of Haleon in a research report on Friday, July 31st. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 370 price target on shares of Haleon in a research note on Thursday, April 30th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of GBX 395.67.

Haleon Stock Performance

HLN stock opened at GBX 369.40 on Wednesday. The company has a quick ratio of 0.93, a current ratio of 0.92 and a debt-to-equity ratio of 52.26. The business’s fifty day simple moving average is GBX 352.14 and its two-hundred day simple moving average is GBX 363.14. Haleon has a twelve month low of GBX 317.80 and a twelve month high of GBX 416.10. The firm has a market cap of £32.54 billion, a price-to-earnings ratio of 20.41, a PEG ratio of 1.49 and a beta of 0.24.

Haleon (LON:HLN) last released its earnings results on Thursday, July 30th. The company reported GBX 8.60 earnings per share for the quarter. Haleon had a return on equity of 10.30% and a net margin of 15.11%. Analysts predict that Haleon will post 19.5033282 earnings per share for the current year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.